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New for Who? Novelty and Continuity in Drug-Related Practices of People 
who Use New Psychoactive Substances 
 
Abstract 
New (or Novel) Psychoactive Substances or NPS are so-called because they are 
characterized by a shared property of ‘newness.’ In this paper we critically unpack 
NPS as a category and as a single object, bounded by a shared ‘newness’, and in so 
doing examine whose ways of knowing are afforded epistemological authority and 
the harms that can emerge from an overemphasis on pharmacological properties at 
the expense of everyday practice. Through a focus on buying and selling NPS 
discussed in interviews with five “at risk” populations in Scotland, we examine the 
ways in which NPS use can in fact be more usefully characterized by continuity with 
existing practices, relationships and identities than by novelty. This finding raises the 
question that if everyday practices are not characterized by newness, what makes 
new psychoactive substances new? Comparison of the discourses of pharmacologists 
and people who use them exposes contrasting claims about the ‘reality’ of NPS: 
while pharmacologists describe their own ways of knowing as real, they often 
downgrade the experiences of those who use them as mere belief; the reverse does 
not occur. A common epistemological hierarchy is shared between pharmacologists, 
and those who use NPS and work with them where everyday practices (often 
characterized by continuity) are devalued relative to pharmacological ways of 
knowing that foreground novelty. When services have finite resources, this 
epistemological authority has significant consequences: when attention is paid to the 
‘new’ (attempting to gain mastery of an ever-shifting drug landscape) it is not being 
paid to the ways in which NPS substances are consumed within wider contexts 
characterized more by continuity with ‘traditional drug’ use than divergence.  
 
Keywords 
New Psychoactive Substances; Drug Buying; Drug Dealing; Drug Treatment; 
Categorization; Scotland 
 
Introduction 
In this paper we ask for whom are New (or sometimes Novel) Psychoactive 
Substances (NPS) ‘new’ and in so doing begin to explore how NPS have become 
constituted as an object. It begins from the voices, experiences and practices of a 
group of primarily in-treatment current and former NPS users from across Scotland. 
The story they tell is rarely one of novelty. Rather, what emerges from their words 
are the myriad threads that tie NPS use practices to older, more established ones. In 
other words, for those who use them, or for this group at least, new psychoactive 
substances are not primarily constituted by their newness. If the everyday practices 
of those who use them are not shaped by newness, if the meanings ascribed to 
them by those who use them are not framed as new, by what processes, through 
the valuation of what sorts of knowledge, did they come to be characterized as new 
psychoactive substances? Where does this focus on newness come from? Whose 
epistemology matters?   
 
We argue that through bringing the voices of those who use NPS into dialogue with 
other sets of practices, other ways of knowing NPS, we can begin to unpack the role 
of epistemological authority in knowing NPS and in constituting them as an object. 
The acronym ‘NPS’ – despite its surface-level ambiguities and vagueness – can be, 
and is used as if it means something, as if it has some sort of stable referent, as 
though it is a tangible object; it is this process of stabilization that reveals the 
knowledge practices that count, and those that do not.  
 
This article takes inspiration from Annemarie Mol’s The Body Multiple (2002) and her 
explorations into how reality does not precede a given object or practices, but is 
rather constituted by them. Following Mol, we shall explore how NPS are given 
coherence as an (often singular) object through the prioritization of pharmacological 
practices over users’ practices, how the costs of these forms of epistemological 
authority are born by those least able to contest them and how treatment often 
suffers as a result.  
 
Multiplicity versus Singularity 
In her pioneering work The Body Multiple: Ontology in Medical Practice (2002), 
Annemarie Mol explores the ways in which medicine in general and atherosclerosis 
of the lower limbs in particular are constituted1, arguing that they are constituted 
not so much by meaning (what atherosclerosis ‘means’ to patients, doctors and 
others) but by practices. In other words, atherosclerosis is enacted by patients, 
surgeons, general practitioners and pathologists. It is through the ways in which 
                                        
1 Atherosclerosis refers to the build-up of plaque in the arteries, which narrows them and constricts 
the flow of blood to extremities.  
atherosclerosis of the lower limb is enacted – how these groups do atherosclerosis – 
that it is brought into being as an object. 
 
A necessary consequence of this focus on practice is multiplicity. The body can no 
longer remain singular in this analysis: for patients, atherosclerosis is brought into 
being through pain when walking; for surgeons by the lack of discernible pulse in 
the ankle and complaints of pain in walking and relief in rest; for pathologists by a 
presence of dye-illuminated plaque and an absence of lumen in a cross-section of an 
artery made visible through a microscope. It is a single thing – it is atherosclerosis – 
but it is multiple. The multiple ways in which it is brought into being as an object, 
the diversity of ways in which it is enacted, mean that this thing, ‘atherosclerosis’, is 
not a single, straightforward object but an entity brought into being through the 
ways it is known: because those ways of knowing are always multiple, it is multiple 
also.  
 
Thus for Mol, reality doesn’t precede practices but is constituted through them. In 
this case, atherosclerosis is brought into being through various technologies, 
including but not limited to reports of pain, blood pressure cuffs, angiography and 
duplex testing. Often, these different ways of knowing atherosclerosis align and a 
decision can be made about whether to perform surgery or not. However, this is not 
always the case. And,  
 
If two objects that go under the same name clash, in practice one of them 
will be privileged over the other… To sustain the singularity of the object one 
signifier must be discarded. (2002, p.47, p.62)  
 
Often this means that if patients’ complaints of pain are at odds with medical tests 
they are disregarded. However sometimes two tests will produce conflicting results, 
and this needs to be resolved – Mol argues that powerful actors resolve such 
disputes through making ontological claims, such that one test can be claimed to 
only ‘seem’ to suggest a particular result while another reveals an ‘in reality’ truth. 
Until the surgery is performed the veracity of these truth-claims cannot be revealed; 
ontological claims make the realities they purport to describe.  
 
What does a discussion on atherosclerosis contribute to understanding substance 
use? The objects, after all, could not be more different: one is a physiological 
consequence of diabetes, the other a set of substances for consumption. But in 
order to address for whom New Psychoactive Substances are new we need to 
understand what New Psychoactive Substances are. To do that, we need to look at 
how they are brought into being – and given coherence as a singular, 
comprehendible object (or not). In a twist of tautology, what coheres them is their 
newness – but it is newness of a particular order. As already noted above, and 
explored in further detail below, for those who use them NPS are rarely defined by 
their newness. Indeed NPS are rarely enacted as a single, coherent object at all. 
Rather, this work of constituting and boundarying NPS as a singular object has taken 
place elsewhere, in the annals of prestigious scientific journals.  
 One of the most striking things in reading about NPS in academic publications across 
different disciplines is how self-evident NPS as a concept is taken to be, as illustrated 
by these examples of the opening sentences of academic papers, which do not then 
continue to provide a definition of NPS,  
  
The last decade has seen a worldwide surge in the recreational use of novel 
psychoactive substances (NPS). (Zawikska, 2017, p. 1)  
 
The increasing supply of novel psychoactive substances (NPS) is changing the 
drug market in a fundamental way. (Anderson & Kjellgren, 2016, p. 283) 
 
These scholars do not need to define NPS because they – and their reviewers and 
editors – already know what NPS means and know their readers will too, and that 
this understanding is a shared one. This is NPS object-making in action: treating NPS 
as a single, bounded entity makes it into a single, bounded entity.  
 
However, it does not take much interrogation to expose the work required to do this. 
For example, Vaiano et al. (2016, p. 441) state NPS are “synthesized by altering the 
chemical structure of controlled compounds, in order to produce new unscheduled 
drugs.” By this definition, they are first and foremost tweaked molecules seeking to 
simultaneously evade detection and/or classification and produce a pleasurable and 
profitable high. But Sutherland et al. (2017) draw attention to “older-new” drugs 
such as DMT (dimenthyltryptamine), synthesized long ago but only recently 
popularized, and ask if these should be included. Others wonder if natural-occurring 
substances such as Hawaiian baby woodrose, long used in indigenous communities 
but only recently popular in the West, should have their place alongside their 
synthesized brethren (Favretto et al., 2013; Tittarelli et al., 2015). Among those 
parties tasked with the boundary work, NPS resists easy definition.  
 
Work has to be done to constitute NPS as an object – it did not emerge into the 
world, new, whole, and complete. However, new psychoactive substances often 
continue to be talked about as if they are not all these diverse things, but a self-
evident reality. This conceptual unity in the face of diversity can perhaps be 
explained in terms of the definitions we found to be most commonly cited among 
scholars who do define what they meant by NPS:  
 
A new narcotic or psychotropic drug, in pure form or in preparation, that is 
not controlled by the [United Nations drug conventions], but which may pose 
a public health threat comparable to that posed by substances listed in these 
conventions. (EMCDDA, 2006, p. 1) 
 
Substances of abuse, either in a pure form or a preparation, that are not 
controlled by the 1961 Single Convention on Narcotic Drugs or the 1971 
Convention on Psychotropic Substances, but which may pose a public health 
threat. (UNODC, 2013, p. iv)2  
                                        
2 UNODC continues, stating “In this context, the term ‘new’ does not necessarily refer to new 
inventions but to substances that have been recently become available.” However, this corollary is 
often missing when cited. 
 Both of these highly congruent definitions define NPS as psychoactive substances 
not controlled by UN Conventions, and that may pose some sort of public health 
threat. While the covered/not covered by UN drug conventions is a relatively clear 
line, the latter clause is not – it is framed in terms of potentialities, rather than 
effects. Any ‘new’ thing, by definition, will have unknown effects, and this state of 
unknowability means that it could at some future point pose a public health threat.   
 
Fraser and Moore (2011) explore this unknowability specifically in relation to 
amphetamine-type substances in Australia, exposing how they are constituted as 
both poorly understood and inherently dangerous. Barratt et al. (2017) pick up on 
this tension in relation to new psychoactive substances-related legislation in 
Australia, arguing that this simultaneous framing as poorly understood and 
inherently dangerous results in Australian policy “tend[ing] to treat NPS as a singular 
category of substance” (2017, p. 22) because of their perceived shared property of 
producing as-yet-unknown “psychoactive effects” in consumers.  
 
In line with these scholars, we argue that NPS gets constituted as an object through 
definitional work that foregrounds unknowability. Within these frequently cited 
definitions, as long as a substance fulfils these three criteria – being a psychoactive 
substance, not covered by UN Conventions, and potentially posing public health 
harm (which they do by virtue of being as yet unknown and unknowable) – they 
become NPS. What all NPS have in common within this definition is a shared 
property of novelty: in prioritizing that over their diversity of effects, meanings to 
those who use them and the like they become singular. These definitions have 
powerful shaping effects because they are frequently cited and therefore easy to 
mistake for a description of what NPS are rather than a particular set of practices 
that bring NPS into being as an object. 
 
Going further, attention must be paid to the choice of language – or more 
specifically the choice to use an acronym – to describe these objects. The label ‘new 
psychoactive substances’ builds the common property of novelty (and thus the forms 
of knowing that foreground novelty) into the language used to describe and group 
hitherto diverse substances. But the acronym NPS goes even further: the overt 
reference to plurality of ‘new psychoactive substances’ gets lost. It is even easier to 
mistake ‘NPS’ for a singular object than ‘new psychoactive substances’. 
 
Barratt et al. play with this when they say “in spite of the (apparently) fluid nature of 
NPS, it is constituted as a largely coherent object that ‘hangs together’, in Mol’s 
terms, as a singular entity, thus obscuring difference” (emphasis added) (2017, p. 
23). Like Barratt et al. (2017) and Fraser and Moore (2011), there is an emerging 
body of critical scholarship seeking to de-obscure that difference. Sumnall et al. 
(2017) highlight the diversity and complexity of both NPS pharmacology and effects, 
concluding that “it is too simplistic to consider these as one class of drug, although 
they are often popularly discussed as such.” Soussan and Kjellgren (2016) similarly 
seek to desingularize NPS, doing so through examining motives for using NPS. By 
focusing on the practices of NPS users it emerges – in striking concordance with our 
own findings – that different motives adhere to different sorts of NPS. They too 
conclude that it is too simplistic to consider these substances as one class of drug. 
Potter and Chatwin (2018) ask similar questions about the apparent distinctiveness 
of NPS, questioning the utility of NPS as a category, arguing that:  
 
the creation of the category [NPS] itself has resulted in significant 
consequences while having neither meaningful coherence or academic utility. 
(2018, p. 2) 
 
This is borne out by Soussan and Kjellgren (2016) when they conclude that people 
who are drawn to different types of NPS have different routes into, through and out 
of use, and that “different pathways to drug use is assumed to be essential in 
enabling effective treatment, prevention and consequently a reduction in harm” 
(2016, p. 78). Thus when treatment and prevention services work within categories 
that prioritize pharmacological over practice-based ways of knowing, the outcome is 
not neutral, and indeed risks potentially harming those seeking support with their 
substance use. 
 
In addition to making this important point, Potter and Chatwin argue that through 
creating the category ‘NPS’, the opposite, ‘not-NPS’, must also be brought into being. 
In this process of creating ‘NPS’ and ‘not-NPS’, ‘NPS’ must be understood as (a) 
having properties in common, and (b) being distinct from ‘not-NPS.’ For them, this 
process obscures far more than it reveals, and it does this by precluding other forms 
of sense-making. As noted above, this matters because prioritizing the practices 
through which newly emergent/rediscovered/popularized substances are constituted 
as ‘new’ is mutually exclusive with research practices that find them in existing 
categories and existing practices. A key example of this can be found in the Drugs 
Wheel (www.thedrugswheel.com), which was central to the definition of NPS used in 
this study, to which we now turn.  
 
Constituting Newness: A Methodological Undertaking 
This paper is a byproduct of another research project. Following a scoping review 
(Fraser, 2014), the Scottish Government commissioned a piece of empirical research 
to ascertain the prevalence, motives, and harms of NPS use in Scotland, with a view 
to inform policy (see [removed for review]). Fraser (2014) identified five groups at 
particular risk of engaging in NPS use:  
• At-risk young people (age 16-21) – for example, care experienced, those not 
in education (YP) 
• Homeless people (HP) 
• Mental Health Service Users (MHSU) 
• People who inject drugs (PWID) 
• Men who have sex with men (MSM) 
 
To garner a comprehensive understanding of this issue, a three-phased, mixed 
methods approach to data collection was taken. This article draws from the data 
collected in Phase One and Two: interviews with people who at the time of interview 
were using or had used NPS, and focus groups with frontline workers. In total, 32 
interviews were conducted with 33 individuals, who fell into one or more of the 
identified “at-risk” groups. Interviews took place across mainland Scotland, primarily 
in recovery-oriented treatment settings (Scottish Government 2008, 2018); 
consequently, participants framed their discussion through a recovery paradigm, 
frequently describing their use in terms of a progression toward eventual achieved or 
aspired abstinence (Neale et al., 2011). The key exception to this was MSM, who 
were recruited online and in gay bars and none of whom saw themselves as being in 
or working toward recovery.  
 
[TABLE 1 – see end of document] 
 
For Phase Two, four focus groups with 42 frontline workers were undertaken across 
urban and rural Scotland; most (20) worked in a drug service, but participants also 
came from prisons, housing, homelessness, sexual, mental health and youth 
organizations.  
 
[TABLE 2 – see end of document] 
 
All interviews and focus groups took place between January and April 2016. This 
timeframe is significant as it followed the drafting, but preceded the implementation, 
of the Psychoactive Substances Act, which came into force in May 2016. Participants 
were asked about what they anticipated the effects of the Act to be. The Act defines 
Psychoactive Substances thus:  
 
any substance which (a) is capable of producing a psychoactive effect in a 
person who consumes it, and (b) is not an exempted substance3. 
(Psychoactive Substances Act 2016, s.2.1)  
 
As a UK-wide piece of legislation, the Act signified the culmination of a series of 
shifts that had occurred in the months and years leading up to May 2016. A range of 
local ordinances led to the closure of shops selling NPS, thus when participants were 
asked about the then-forthcoming ‘ban’, they often answered retrospectively, 
reflecting on the impact of locally implemented by-laws prohibiting the legal sale of 
NPS in shops.  
 
Defining NPS: How particular substances came to be included in the study 
A particular challenge of the early stages of the project was anticipating that 
participants may not be familiar with the object ‘NPS’ and to identify which 
substances we were and were not interested in understanding the use of: in short 
which substances were and were not NPS for the purpose of this study (see 
Measham and Newcombe, 2016, on the impact of this lack of clarity on drug 
monitoring). Some substances were considered straightforward. Brightly colored 
packets of synthetic cannabinoids going by names such as Exodus, Black Mamba, 
and Clockwork Orange were bound up with new challenges experienced by services 
and the subject of a “moral panic” (Cohen, 1972), as numerous documentaries and 
                                        
3 Exempted substances are: controlled drugs (within the meaning of the Misuse of Drugs Act 1971), 
medicinal products, alcohol or alcoholic products, nicotine and tobacco products, caffeine or caffeine 
products and any substance which “is ordinarily consumed as food and does not contain a prohibited 
ingredient.” 
newspaper articles described new social problems resulting from their existence (e.g. 
‘Horror as Lethal Spice “Zombie” Drug Epidemic Spreads among Homeless in 
Glasgow’, Daily Record, 2017; ‘Living Life as a “Zombie” on Spice’, BBC, 2018). 
Similarly the new raft of stimulants going by names such as Charlie Sheen or GoGain 
(and designed – or at least marketed – as a licit alternative to scheduled stimulants 
such as cocaine), new empathogens such as mephedrone (designed, and originally 
marketed, as alternatives to ecstasy), and new psychedelics, which tend to go by 
names sounding closer to chemical formulae such as 25I-NBOME, 5-MeO-DMT or Al-
LAD were included.  
 
However, the inclusion of some substances was debated. What, for example, is the 
place of salvia divinorum? What of the benzodiazepine family? Were these more 
usefully understood as plants, diverted pharmaceuticals or New Psychoactive 
Substances? Dwyer and Moore (2013), who used Law (2004) as a theoretical frame 
to unpack multiple ontological understandings of methamphetamines, explain:  
it is important to pay attention to the politics of what is made present and, 
correspondingly, what is absent, what is silenced, and what is made Other. 
(Dwyer & Moore, 2013, p. 204) 
 
Given the focus on policy, and thus the focus on harms, these substances were 
included because they had been identified to embody new problems in need of 
solutions, thus the definition finally adopted in the study was pragmatic, rather than 
conceptual. To understand NPS as an object required work: it was not a given and it 
was far from stable.  
 New Psychoactive Substances versus Legal Highs 
A further challenge posed by this project was what to call this pragmatically cohered 
group. The phrase most frequently used in research and policy is ‘New Psychoactive 
Substances’, a phrase deliberately chosen to distance itself from ‘Legal Highs.’ As 
has also been noted elsewhere (Measham & Newcombe, 2016; Potter & Chatwin 
2018), the language of policy and research is that of novel or new psychoactive 
substances (NPS). Yet this phrase was next to meaningless for our study 
participants; it was a category (or object, Mol, 2002) that simply did not exist for 
them. Yet the alternative – ‘legal highs’ – was problematic because it appeared to 
place these substances on one side of a legal/illegal binary and whether a packet of 
a given substance comprised only licit substance(s) in that place, at that time, was 
far from certain (Frinculescu et al., 2017; Ramsey et al., 2010). Yet the language 
remained. While we avoided it, our study participants did not. They frequently spoke 
of “legal highs” and “legals” and even of being “legalled” (i.e. under the influence of 
a specific legal high). Participants did not necessarily mean the same thing when 
they used this term: some used 'legal highs' to refer only to synthetic cannabinoids; 
others to any drug bought in a shop; others to purchased prescription 
pharmaceuticals. Just as there was no stable NPS, there was no stable legal highs 
either.   
 
Analysing Newness 
The qualitative data discussed here were initially analyzed to identify motives for, 
and harms of, NPS use as identified by those who currently or formerly used them, 
and frontline staff who worked with them. Interviewees selected themselves into the 
study in response to the following wording on recruitment posters: “Have you ever 
taken a legal high or a New Psychoactive Substance? Are you aged 16 or over?” All 
had taken at least one substance defined as NPS for the purpose of the study at 
least one time. Participants were asked about: what NPS they had tried and where 
appropriate continued to use; positive and negative effects; attempts to stop use; 
experiences of treatment; and views on the (then-forthcoming) Psychoactive 
Substances Act. These interviews were then transcribed, anonymized and coded 
using Quirkos qualitative software for themes of motives for use and harms of use 
(Braun & Clarke, 2006).  
 
Following the initial analysis in 2016, data were coded again in 2018 for ‘newness’ 
for the purposes of this paper; ‘newness’ was not asked about directly in interviews. 
Transcript segments were initially coded as either ‘new’ or ‘not new.’ All codes were 
then checked against the available literature. Segments related to motives, such as 
‘being able to buy from a shop’ or ‘being able to sample many varieties before 
finding the one you like’ were coded as ‘new,’ and ‘concerns about purity’ or 
‘recovery prompted by pivotal moment’ were coded as ‘not new.’ This distinction was 
based on whether there was an established evidence base to show that these 
aspects of drug use experience precede the emergence of New Psychoactive 
Substances as an ‘object’ or not.  
 
Using newness as an analytical category proved problematic: segments on such 
topics as ‘being able to buy online’ or ‘being able to research options before buying’ 
raised profound questions about what constitutes newness, and the ways in which 
new psychoactive substances are entangled with other processes, other 
developments, and other forms of newness. Some participants in this research 
distinguished NPS from their traditional forerunners because they could buy NPS 
online, yet other research notes that the Internet has long operated as a space 
where commodities both licit and illicit can be purchased (Martin, 2014; Masson & 
Bancroft, 2018). Is the newness of being able to research or buy NPS online about 
‘new’ substances, or ‘new’ communication technologies and online spaces? As 
Internet-enabled, mobile devices become increasingly popular and affordable, digital 
spaces have become more accessible and responsive to wider audiences. The 
technologies that underpin the production, consumption and knowability of NPS are 
not static.  
 
Ethical Considerations 
This study sought to understand people’s experiences in their own terms. 
Recruitment materials used the language of both ‘new psychoactive substances’ and 
‘legal highs’ and we worked closely with treatment providers to inform them of the 
study to aid recruitment of people who may use or have used NPS but did not use 
the language of NPS or legal highs to describe their practices. All interviews were 
conducted in places familiar to participants, usually in the treatment setting where 
they had been recruited, and all interviews were conducted by an interviewer with 
extensive experience of the drug treatment field. It was made clear to participants 
that they did not have answer any questions they did not want to, and could end the 
interview when they wanted. All interviewees were offered a £10 high street voucher 
to thank them for their time and, critically, their expertise. We began from the 
position that people who use drugs should be recognized as the experts in their own 
lives and that all expertise should be appropriately recompensed (Pickering, 2018). 
This project received ethical approval from the UK’s Health Research Authority’s 
National Ethics Service (Ref: 15/WS/0210). 
 
Threads Broken and Rewoven: Rupture, Continuity and the ‘Arrival’ of NPS 
As noted above, this is not a paper based on a ‘general’ NPS using population. With 
the partial exception of Men who have Sex with Men (MSM), our participants were 
marginalized, often multiply so. Many had experienced homelessness, many had – or 
had had – mental health problems; almost all were in contact with drug treatment 
services. Their stories, then, are particular stories. No interviewees described their 
first encounter with drugs as being with NPS; all were experienced drug users, the 
majority were polydrug users, and many described highly challenging lives and drug 
use practices.  
  
Participants told us about using ‘legal highs.’ When probed, claims such as “I’ve tried 
every legal high basically there is” (John, 26, MHSU) or “when you take legal highs, 
the actual sniff” (Gary, 39, MHSU/HP) revealed that different participants used the 
phrase “legal high(s)” to refer to different things – and generally to the substance(s) 
that they personally consumed (in John’s case synthetic cannabinoids, in Gary’s, 
stimulant NPS). Substances outside their personal repertoire simply did not feature 
or warrant inclusion under the title ‘legal highs.’ ‘Legal highs’ resisted a shared 
reference point across those who used them, while being used as though mutually 
intelligible in an interview setting.  
 
Further, when asked about the NPS or ‘traditional’ drugs they used, participants 
generally demonstrated a lack of understanding of, or indeed particular interest in, 
this distinction. As Thomas (45, MSM/PWID) demonstrated when he replied “speed” 
to the question “what did you use the first time you used a legal high or new 
psychoactive substance?”, our interviewees were not always clear on whether the 
substances they used were NPS or not, or legal highs or not. Similarly, Luke (20, YP) 
included “downers” (a category in which he included cannabis), Valium, 
mephedrone, and Kryptonite (a synthetic cannabinoid) among the list of illegal drugs 
he had used. When asked specifically about the status of mephedrone, Hugh (61, 
MSM) explained that “they’re all legal and that [he] had never paid much attention 
but that, yes, it’s definitely not illegal,” despite mephedrone being made a Class B 
drug in 2010.  
 
However, this does not mean that our participants did not classify the substances 
that populated their personal drug landscapes. Far from it. These distinctions were 
just of a different order, and concerned with the everyday pleasures and practices of 
use, rather than where they stood on an NPS/traditional, or in most cases even a 
legal/illegal, binary: as Daniel, Peter and Andrea illustrate, our participants 
distinguished between drugs they would use again and drugs they would not, 
“junky” drugs and non-”junky” drugs, and substances suited or not suited to one’s 
preferred route of administration.   
 I thought it was a cannabis joint … I started hiding under my bed for four 
days. It is something I wouldn’t ever do again, it was actual crazy. (Daniel, 
17, YP/HP/PWID) 
 
It [synthetic cannabinoids] was a total junky wee thing to do, man. I just 
don't know why these wee Goths … sit and smoke it all the time because it 
was nasty, man. It was probably just as bad as fucking kit [heroin]. (Peter, 
17, YP/HP/PWID) 
 
He [the shopkeeper] told us what the best [synthetic cannabinoid] would be 
to do, but he told us to smoke it, but we injected it. (Andrea, 34, HP/PWID) 
 
In talking about the choices they made about the substances tried, continued with, 
and sought to stop using, participants merged NPS and ‘traditional’ drugs together. 
What mattered to them were distinctions related to their everyday practices and 
sense of identity. 
 
Sense-Making: Social Inequality & Technological Advances 
Potter and Chatwin (2018) propose an alternative to pharmacological forms of 
sense-making predicated on locating specific, ‘new’ substances within broader 
societal (rather than chemical analytical) processes, drawing on two such processes 
by way of illustration. These are (1) social inequality and (2) technological change. 
To explore social inequality they use Alexandrescu’s sociological analysis of NPS use 
in Romania to explore what happens when NPS is reframed not as driver of harms 
but as byproduct of other factors. Alexandrescu argued that when examined from 
this perspective, epidemics among vulnerable populations occur less because new 
drugs appear, than because of the “deeper, structural economic problems and 
inequalities” (2017: 1) that shape the lives of people who use NPS more generally. 
For both Alexandrescu (2016, 2017) and Potter and Chatwin (2018), these problems 
manifest in relation to whichever substances are available at the time, but are 
caused by deeper social issues. Focusing on the substance rather than underlying 
inequalities will necessarily produce findings that the substance – and specifically its 
novelty – is the cause of the social harms experienced by its already-vulnerable 
users. Refocusing attention to underlying structures reverses this and locates the 
use of a particular substance as an expression of, and response to, preexisting 
harms.  
 
In our study, participant groups were selected because they were understood to 
already be at the sharp end of “structural … problems and inequalities” and as a 
result particularly “at risk” of problematic NPS use (Fraser, 2014; [removed for 
review]). However, they did not understand themselves to be particularly “at risk” of 
NPS, nor consider themselves as “NPS users” at all in some cases. They were people 
who were in contact with drug services because they (or someone else) understood 
their substance use to be problematic in some way, or a barrier to achieving other 
goals. Whether it was ethylphenidate or heroin, cocaine or Ching, the solution to the 
‘problem’ lay in recovery – the shaping concept of Scottish drugs policy and defined 
in the-then Scottish Drugs Strategy, The Road to Recovery (2008) as:  
 a process through which an individual is enabled to move on from their 
problem drug use, towards a drug-free life as an active and contributing 
member of society. Furthermore, it incorporates the principle that recovery is 
most effective when service users’ needs and aspirations are placed at the 
centre of their care and treatment. In short, an aspirational, person-centred 
process. (2008, p. 23)4 
 
For our participants, the ‘NPS’/‘not-NPS’ binary was, in practical terms, largely 
irrelevant. It was poorly understood and did little to shape their routes in, through, 
and out of substance use. However, when discussed with frontline workers, much 
talk addressed the ever-shifting NPS landscape and their knowability. As stated in 
the Glasgow focus group,  
 
The type of NPSs out there, it’s forever evolving, forever changing and it’s 
being able to access up to date information. 
 
This ongoing, shifting landscape was experienced by many frontline drugs workers 
as being substantially different to substances with longer histories of use:  
 
Traditionally we’ll say ‘Heroin: this is the side effects, this is this, this is that, 
this is the withdrawal symptoms …’ but because there’s such a plethora of 
                                        
4 The current Scottish Drug Strategy defines recovery as “a journey for people away from the harm 
and the problems which they experience, towards a healthier and more fulfilling life” (2018, p. 26). 
different chemicals and changing chemicals, what are you going to do? 
(Glasgow Focus Group) 
 
Service users also experienced this; some interviewees commented on services’ lack 
of knowledge:  
 
They [drug service] didn’t know enough about the synthetics [synthetic 
cannabinoids]. They knew bits and pieces maybe about powders and pills 
and they didn’t know enough about synthetics to help me. (Kieran, 46, MHSU) 
 
Kieran expressed frustration at the lack of knowledge within services about the 
particular substances he consumed. While the anxieties of the former may have 
been driven by the frustrations of the latter, there is a critical difference: people who 
use drugs tended to be concerned with knowledge about the specific substances 
they consumed, whereas workers expressed anxieties about NPS as a class made up 
of an ever-expanding panoply of specific substances. While workers could 
theoretically build their knowledge of specific substances, the fact that the class of 
substances known as ‘NPS’ consists of all ‘new’ drugs in a globalized network of fast 
turnaround development, production, transportation and consumption means that 
they simply cannot gain mastery of the class itself. As soon as they know all there is 
to know about the substances that comprise NPS in a given moment, the individual 
substances of which the group comprises has changed again (Measham & 
Newcombe, 2016).  
 
The second alternative form of sense-making Potter and Chatwin focused on was 
technological change, asking what happens when we contextualize NPS as part of – 
rather than outside of – wider processes of evolving chemical and horticultural 
techniques, and new media technologies. They concluded that within those contexts, 
NPS are “not particularly special.” These technological changes have driven, and 
been driven, by new forms of social engagement spurred by Web 2.0, faster forms 
of international postage, smartphone technology, and the like. Within this, NPS is 
neither a driver nor consequence but intimately bound up in a complex of 
interlinked, technological innovations.  
 
We support Potter and Chatwin’s contention that “[i]t is not clear that anything 
objectively unites NPS in a way that delineates them from pre-existing categories of 
illicit drugs” (2018, p. 331), and it is this very lack of distinction that exposes the 
volume of work that is required to shore up ‘NPS’ against ‘not-NPS’, in turn, exposing 
the forms of knowing NPS that are foregrounded in seemingly abstract and universal 
‘definitions’ of NPS. To do this, we focus on a single site of social and technological 
innovation – purchasing NPS – and how the utilization and evolution of these 
technologies are intimately bound up with more existential questions of knowability, 
and whose knowledge counts.  
 
Buying NPS  
There were three key routes participants described to access the substances we 
were interested in: shops, dealers, and the Internet. Headshops specializing in the 
sale of mainly cannabis-related drug paraphernalia were well positioned to adapt to 
the arrival of brightly colored packets of (at least temporarily) legal substances, likely 
to be of interest to their patrons. Six of the eight participants who described buying 
NPS in shops discussed buying synthetic cannabinoids, while the remaining two 
detailed buying Burst (ethylphenidate).  
 
Blurred Boundaries: Shops and Dealers 
Choosing Shops 
The brick-and-mortar shop as a site of drug sales can be seen as a significant 
development in UK drug markets; they were a new space, through which new types 
of drugs characterized by ‘reliability’ and ‘consistency’ could be bought. It provided a 
means of accessing mood-altering substances not predicated on one’s social 
networks.  
 
Over his drug-using career, Luke (20, YP) had moved from consuming primarily 
cannabis to primarily synthetic cannabinoids to aspiring recovery at the point of 
interview. In addressing the appeal of synthetic cannabinoids, he discussed the ease 
of buying from shops,  
 
It was just knowing that all you had to do was walk with my dog, run to that 
shop … hand over the money, that was that. Guaranteed. Sealed packet. Not 
opened.  
 
For Luke, the shop as a site of purchasing substances represented something new: it 
had predictable, reliable opening hours, and the products sold were “Guaranteed. 
Sealed packet. Not opened.” Like any new development, it is only new in relation to 
that which preceded it (Hutton & Farías, 2017), and this was no different for Luke. 
Luke began this discussion of buying synthetic cannabinoids from shops by talking 
about buying cannabis from dealers,  
 
Getting a bag of weed, if it wasn’t a regular dealer, it was like, ‘What is this 
stuff going to be like? Can you trust him? Is it going to be on weight?’ 
 
Buying in shops were presented directly in contrast to the anxieties of finding a 
dealer, ensuring quality assurance and avoiding being ‘ripped off.’ The shop as site 
of security – as ‘new’ – emerges from this contrast.  
 
For others, shops were a site of asociality: as one of the three participants who 
described eagerly awaiting the arrival of the Psychoactive Substance Act explained,  
 
Nobody I knew smoked it [synthetic cannabinoids]. And up to this day, I’ve 
not been in contact with anybody face-to-face that smoked it … If the shop 
haven’t got it, I’m not going to go to dealers, cos I don’t know dealers. 
(Kieran, 46, MHSU) 
 
Kieran, like some others who bought exclusively in shops, did not know any street 
dealers and anticipated the banning of shop sales as foreclosing the only available 
route to accessing their substance(s) of choice.  
 
One possible consequence of this emergent technology of purchase might have been 
that dealers, seeing a loss of business from people like Luke, changed their practices 
to become more shop-like. However, this is the reverse of the pattern that emerged 
from our participants’ accounts. Instead, shops came to increasingly resemble 
dealers. Participants described shop keepers who would sell to them ‘on tick’ (i.e. 
sold on the agreement that the buyer would pay for the goods at a future point); 
shops coming to mirror the hours in which buyers bought from dealers; and shops 
undermining the very thing Luke valued (“Guaranteed. Sealed packet. Not opened”) 
by taking sealed packets that retailed at £10 a packet and splitting them into two for 
sale at £6 each to cater for lower income and customers who operated on a shorter 
temporal loop. As Nicola (32, PWID) explained,  
 
The shops that were selling them, they started just acting like your dealer 
because then they were putting signs outside their shops, deliveries and 
everything, so they were just like a dealer, you’d be able to phone them at 
any time and then they’d come and meet you.  
 
Thus when thinking about the ways in which new practices constitute a new object, 
shops both did and did not constitute NPS as ‘new.’ The “guaranteed” nature of the 
transaction and independence from existing social networks that marked shops out 
as distinct from dealers helped constitute the substances sold within them as ‘new.’ 
They produced new user groups and new problems, both in need of solutions while 
also quickly adapting to local markets, adopting dealer-like characteristics.  
 
Choosing Dealers 
Despite the availability of shops, dealers still retained their predominant position in 
the drug-using careers of our participants. Many discussed preferring the familiarity 
of buying from dealers even when they knew that more mainstream alternatives 
existed. Andrea (34, HP/PWID) explained that:  
 
If you couldn’t get it [Magic – ethylphendiate] from anybody here, which was 
quite unusual, there was the shops in [town] that you could go to.  
 
For Andrea and others, shops were a resource – but a resource of last resort. Their 
reluctance to choose shops is a reminder that the existence of new technologies 
such as shops does not necessarily produce uptake of those technologies – if 
anything, the emergence of shops as a site of sales exposed the durability of 
traditional and established forms of exchange.  
 
But what of the “guaranteed” qualities of shop-vended products in relation to dealer-
sold ones? As previously noted, this was not a quality equally valued by all – 
participants like Luke (20, YP) saw this as a noteworthy and preferential difference 
from buying from dealers, but other participants prioritized price and ease of access 
over questions of quality control and consistency. Jessica (35, HP/PWID) reflected 
on the knowability of Magic [ethylphendiate] when bought from a dealer (her 
preferred route):  
 
[I bought Magic] through a dealer, and so I’ve not got a clue what I was 
taking … it might have been different ones, and that’s where the varying hit 
comes from, I don’t know. I just knew it as Magic … it could have been 
anything. 
 
Akin to toxicological discussion of the composition of NPS brands (see, for example, 
Measham, 2019; Ramsey et al., 2010; Smith et al., 2015), Jessica experienced the 
composition of Magic as variable in both effects and strength: it was both 
qualitatively and quantitatively unstable. However, this unknowability was not a 
product of NPS, it was not new; it was a familiar feature of buying from dealers 
(Lakhdar et al., 2013). Indeed, Magic’s unknowability was consistent with Jessica’s 
expectations of what the process of buying and using substances was like:  
 
I was already doing that [using without knowing what it was cut with] with 
heroin … We know heroin is cut with loads of crap, we know that it does 
awful things to us but we still use it. (Jessica, 35, HP/PWID) 
 
What is particularly striking about the ways that Jessica and Andrea talked about 
buying Magic of variable quality from dealers was that they knew they could buy it in 
a shop if they had wanted to. They could have had, or at least pursued, the same 
“guaranteed” experience that Luke did. It was about choice, in a space where choice 
was typically limited by one’s resources and connections. And they chose not to.  
 
Choosing Online and the Emergence of (not so) New Mediating Roles 
While the ‘legitimacy’ of shops attracted some, it repelled others. Through this, new 
mediating roles emerged. This can be located in a wider set of trends away from 
dealer/consumer binaries towards new forms of distribution through ‘social supply’, 
‘sorting’ and the like (Coomber et al., 2016; Parker, 2000). Three participants raised 
at least partially financing their own use by buying substances for others and being 
“given” a cut in exchange. Moira (39, PWID) described sourcing mephedrone for 
friends and acquaintances too wary to go into shops “in case they got attacked”: 
 
I started, like I was able to go and get it [mephedrone], so folk would come 
to me, ‘Moira, do you want to go and get it?’ ... At the end, my habit was 
funded cos everybody was coming, and I was taking a fiver off everybody, 
they were giving me bits, and all the rest of it.  
 
Shops, then, did not replace prior social networks of dealing, supply and ‘sorting’ but 
came to be embedded within them. Nor did the Internet. Rather, the emergence of 
brick-and-mortar and online shops created new niches for individuals to occupy 
within the flows between producers and consumers. Tiffany (28, MHSU) and Samuel 
(19, YP/HP), along with several of the younger participants, had discovered that 
buying online afforded better quality at a better price, but also that, as Tiffany says,   
 
I can make money [when] somebody else orders something or I order 
something for them and get it and then they give me, whatever, a couple of 
joints’ worth.  
 Like Moira, Tiffany discovered that the capacity to function as an intermediary 
between vendor and consumer enabled her to “make money.” Samuel (19, YP/HP) 
reflected at length on this intermediary role and the barriers to accessing online 
sales that existed for some consumers:  
 
In [small town] you get quite a lot of folk that are getting it through dealers. 
But like there’s a few people, like a certain handful of folk that know about 
online and have got the money to just frequently get it online…but most 
people that are drug addicts – like it’s the same with smack [heroin] – they’re 
just buying tenner [£10] bits on the street. 
Why do you think people buy from the streets rather than…? 
Because they can’t afford it online. Plus they don’t understand it, right, where 
to get it from online, what websites, and plus they might not have an account 
or they might not have enough money in their bank, plus they want it there 
and then, they don’t want to have to wait a day or two to get it, you know 
what I mean? 
 
Alistair (28, MHSU) was such a person. He knew that it was possible to buy the 
substances he wanted at a cheaper rate online, but he just could not build up the 
necessary “lump of money” to buy this way, explaining:  
 
I just get it off folk on the street…folk just sell it outside. 
And is it cheaper?  
£6 a gram, £6 a gram…You can get it cheaper online if you buy it in bulk. You 
can buy 100 gram online for about three or four hundred quid.  
Why do you choose to buy it from people you know?  
I’ve never got a lump sum of money to go and buy it online. 
 
Like Alistair, Samuel flags up the lack of economic capital as a barrier, but also other 
potential barriers such as having a bank account, the necessary skills and knowledge 
and – critically – the patience to wait for delivery. Even though new forms of 
purchase were available and known about, they remained inaccessible or less-
preferred to buying within an established in-person social network for many.  
 
For our participants, using the Internet to purchase NPS reflected wider generational 
patterns of Internet usage (see Bolton et al., 2013; Joiner et al., 2013; Orsolini et 
al., 2015 on NPS). However, as Samuel highlights, these new forms of 
connectedness depend on a range of factors, including digital literacy (Rowsell et al., 
2017), physical resources such as owning relevant hardware, and financial resources 
to both pay for access and to purchase the substance itself. As Warf (2012) notes, 
there are many factors that make up the “digital divide” and our participants 
reflected this diversity. While those who were more open to buying online tended to 
be of the “digital native” generation5 and more familiar with using technology in their 
everyday lives, they had far from consistent views on the value of the online sphere:  
 
What do you prefer about online?  
                                        
5 See Prensky’s (2001) discussion of ‘Digital Natives’ and ‘Digital Immigrants’. 
It’s a lot cheaper, I can make money. It’s a lot cheaper. Ten gram of really 
good stuff for £25 compared to three gram of shit for £20. It doesn’t even 
compare, do you know what I mean? (Tiffany, 28, MHSU) 
 
No I never bought on line, no.  
Ok, any particular reason you didn’t?  
I don’t trust the Internet, as much as a I love it I don’t trust it. (Colin, 27, 
MHSU) 
 
The choices people made about where to source their NPS were not automatic 
responses to particular substances or to the emergence of ‘new’ technologies. They 
reflected the social worlds with which people were familiar – and new technologies 
such as brick-and-mortar and online shops fitted into that existing social world. They 
attracted some, but felt alien or inaccessible to others; they facilitated the 
development of new intermediary roles based on existing relationships.  
 
Locating this within Potter and Chatwin’s analysis opens up space to decenter the 
substance, and foreground relationships to explore the continuities over the 
ruptures. Viewed through a substance-specific lens, NPS can be seen to drive new 
social spaces (brick-and-mortar and online shops) and new relationships (with 
shopkeepers, new kinds of intermediaries, and online vendors). Look through an 
online retail-specific lens, however, and patterns of access to NPS become a 
byproduct rather than a driver of change. Using the Internet to buy and sell goods 
vastly predates the emergence of NPS (for example, Amazon and eBay launched in 
1994 and 1995 respectively). Despite the closure of brick-and-mortar shops and the 
banning of online sales with the passing of the 2016 Psychoactive Substances Act, 
NPS continue to be purchased in the UK with relative ease in online shops on both 
the Clear-Web (the visible, search engine-indexable, easily accessed part of the web) 
and Dark-Web (sites not accessible through traditional browsers or traditional search 
engines, access to which requires specialist knowledge and equipment). Strikingly, 
such sites resemble and mimic the features – such as escrow and vendor and buyer 
star ratings – of Amazon (and Amazon Marketplace) and eBay (Barratt, 2012; 
Martin, 2014). From the perspective of online retailing, rather than substance use, 
then, NPS can be seen as just other commodities purchasable online. As Michelle 
(16, YP) recounts, the rhythms of shopping for synthetic cannabinoids as a person 
who lives near but not in a major city mirrors those of almost any other commodity:  
 
[I buy it] off the Internet, or there’s a shop in [city] we got it from a few 
times … Whenever like me and my pals went down to [city] we’d always stop 
in at the shop but if we didn’t go down to [city] we’d order it off the Internet 
every couple of days. 
 
Online retailing has become increasingly sophisticated, building upon the foundations 
laid by Amazon and eBay over 20 years ago. Michelle’s narrative highlights the ease 
with which consumption can work in 2019, and the ease with which some can switch 
between brick-and-mortar and online shops for the commodities (be they NPS or 
not) they wish to consume.  
 
In discussing why they used online stores, our participants discussed assuming that 
producers refine their product in response to consumer feedback, shopping around 
until you find the product that suits you, and being able to research products online 
before you bought them. Viewed through a substance lens, these are ‘new’ features; 
they represent a rupture with dealer-bought, ‘traditional’ drugs. Yet when viewed 
through a technologies lens, they are not new at all. Amazon, eBay and the like have 
long had customer reviews and vendor ratings built into their platforms; peer-led 
forums in which users of different substances can share their experiences and seek 
advice have a history almost as long as the Internet itself. All these practices are 
practices that many people, and particularly young people for whom the Internet has 
been a part of the social landscape their whole lives, already engage in in other 
aspects of their lives. You can shop around for drugs as easily as for shoes; you can 
research which new NPS to try next as easily as researching a new biro. Thus when 
we de-center pharmacology in favor of practices, NPS do indeed emerge as not 
particularly special, and do emerge as not particularly new.  
 
Taking Potter and Chatwin’s call to displace the centrality of substance in addressing 
NPS use opens up alternative perspectives directed toward underlying social 
structures and inequalities or developing technologies. By exploring in some detail 
how our participants bought (and occasionally sold) NPS we have been able to 
decenter substance in favor of technologies – in this case technologies of acquisition 
– to provide empirical weight to Potter and Chatwin’s claims and open up ways of 
thinking about NPS that expose (and in exposing, create) them as neither 
particularly new nor particularly special.  
 This process of exposing a reality of NPS use characterized by continuity over 
rupture and by forms of social relationships over forms of substance is an attempt to 
create that reality also. That reality comes into conflict with ways of knowing, ways 
of making truth-claims about NPS that do center on substance, and do center on the 
new.  
 
Epistemological Authority and the Knowability of NPS  
NPS are rendered knowable in a range of ways. For Jessica and her peers, who 
preferred to buy their Magic (ethylphenidate) from dealers than from shops, the very 
inconsistency of the substance as they consumed it and the varying hit it produced 
was what made it familiar for them. It was easy to draw comparisons with the 
heroin it supplanted in their drug use repertoire as it was variable, inconsistent, and 
“cut with loads of crap too;” it was the very inconsistency of ethylphenidate that 
made it consistent, predictable and knowable.  
 
By contrast, individuals such as Luke framed the knowability of the NPS they used 
very differently. For this group, knowability resided in the familiarity of shops: in 
their layout and appropriate relations between shopkeeper and customer; and in the 
homogeneity of product: just as McDonald’s produces “predictable food” (Ritzer, 
2013, p. 97) through a consistent and identical process, so too did NPS 
manufacturers. However, just like McDonald’s food, while you can control even the 
width of a pickle slice, ultimately there will always be marginal unpredictabilities 
when it comes to ingredients, but, “Whatever the (slight) unpredictabilities in the 
food, the packaging… can always be the same and imply that the food will be, too” 
(Ritzer, 2013, p. 97). These were drug consumers immersed in a social world of 
product standardization, and product standardization signaled through consistency of 
packaging.  
 
Packaging shapes expectation. As Moerman (2002) has explored in relation to 
pharmaceutical medicines, “placebo effects” (a term he rejects in favor of “meaning 
responses”) abound. He cites multiple studies showing that people feel the effects of 
both active and inert medications differently depending on color, tablet or capsule 
form, packaging and more. He attributes the effect of aspirin to “a combination of 
the actions of the acetylsalicylic acid, and the meaning of the pill and, perhaps, its 
brand name” (2002, p. 70-71). Moerman argues persuasively that “meaning 
response … is a cultural phenomenon” (2002, p. 71) and that attempts to locate the 
efficacy of a particular drug in its pharmacological properties misses the complex 
ways in which drug effect are shaped by expectation and the meanings nexuses 
within which they move.   
 
“Meaning response” in combination with “McDonaldization” enable us to think about 
pharmacological effects in context – in the context of packaging, and the wider 
realm of shared symbols. This gained expression in varying ways, but primarily 
through the pursuit of something “better”, or for finding the brand that worked for 
you after a period of exploration:  
 
Obviously using Ching [NPS stimulant, marketed as similar to cocaine] 
consistently you get used to it so you don’t get the same hit so you move 
onto something, well obviously better. (Claire, 30, HP/MHSU/PWID) 
 
I tried every legal high [synthetic cannabinoid] basically there was. And then I 
was Exodus man, I just found that that that was better than all the rest of 
them, so now I’m still on it. (John, 26, MHSU/PWID) 
 
Viewed pharmacologically, this expectation of consistency was often misplaced. 
Indeed, lab testing of the contents of these packets has shown that packets do not 
always display their ingredient(s), and where they do, “for most brands, serious 
mislabelling was encountered” (Frinculescu et al., 2017, p. 330). Where this 
happened, stated contents could be substituted with substances licit (Davies et al., 
2012), illicit (Smith et al., 2015) or both; and that “there is poor consistency in the 
contents of legal highs purchased over the internet” (Ramsey et al., 2010, p. 778), 
differing between vendors (Wood et al., 2012), between packets, and even within 
them (Frinculescu et al., 2017). As a result,  
 
Even when users believe that they are buying the same product, a number of 
studies have shown that the active ingredients may change with time. (Wood 
et al., 2012, p. 1125)  
 
Thus the experiences of our participants who bought such packets provided were 
strikingly at odds with the experiences of lab technicians. To return to Mol, they 
were one object with two competing realities. How can this disjuncture be accounted 
for? Which reality wins? Which one is the reality, which is the real nature of this 
object? And who has the authority to make those claims and be taken seriously? In 
attending to the language through which those who talked or wrote about their 
understandings make their claims it becomes clear that everyone was making claims 
about the true nature of NPS, but that these claims were framed somewhat 
differently.  
 
The NPS buyers and users with whom we spoke made ontological claims about their 
substances of choice – they knew them to be consistent within and between packets 
and for this to be true; they did not make claims of any sort about other ways of 
knowing and consequent truth-claims about NPS. From this perspective, there was 
only one object and one reality; adjudication between competing realities was not 
required. By contrast, pharmacological research is specifically interested in 
adjudicating between these competing realities (and thus ways of knowing what is 
really in NPS packets). In Wood et al. (2012, p. 1125), for example, readers are told 
that people who use NPS “believe they are buying the same product” (emphasis 
added) while laboratory testing reveals the “actual contents of the products” 
(emphasis added).  
 
At this point it is useful to return to Mol (2002) and her argument that when two 
ways of knowing a single reality come into conflict (such as when patient accounts 
of pain conflict with test results) one truth-claim is given precedence of the other, 
and that is usually the truth-claim of the doctor over that of the patient, but critically 
the way this is done is key: she argues that one must be dismissed as belief to 
enable the other to stand unopposed as true, as the (singular) reality. And just as 
bodily ways of knowing atherosclerosis are usually dismissed by holders of medical 
expertise in favor of their own technologically informed knowledge as the knowledge 
of the patient’s body, so too here we see technologically mediated forms of expert 
pharmacological knowing being brought into conflict with bodily mediated forms of 
personal experiential knowing by those who use them. And here too, the latter is 
dismissed by the holders of pharmacological expertise in favor of their own 
knowledge as the knowledge of the properties of NPS substances and packets. Users 
believe, pharmacologists know. At least according to pharmacologists. While 
expressed with the best of public health motives, the language of actuality and belief 
assert an epistemological authority from a position of authority. In that process, 
users’ own understandings of their bodies and what they put in them are, at best, 
devalued and dismissed as mere “belief” when it comes into conflict with what 
“actually” happens.  
 
This slippage produces significant consequences, and both drug service users and 
providers shared a common set of anxieties about drug services’ inability to provide 
their clients with appropriate support, because they lacked the appropriate 
knowledge of NPS. When NPS are framed as a set of substances that share 
structural novelty in common, that are understood as ever-evolving, ever-changing 
and internally inconsistent, what both clients and providers wanted was for providers 
to have mastery of the pharmacological properties and physiological effects of each 
substance:   
 I think it’s about getting up-to-date information as well. Because, you know, 
the type of NPSs out there, it’s forever evolving, forever changing and it’s 
being able to access up-to-date information. (Glasgow Focus Group) 
 
It’s just recently everybody seems to [be] taking them [NPS] so they 
[services] probably don’t ken [know] much about them. The likes of kit 
[heroin] and all that, they sort of know the stages, like what you’re going to 
be like if you never had the stuff, but with that [NPS] they don’t really ken. 
(Nicola, 32, PWID) 
 
And this produces solutions to the ‘problem’ (Bacchi, 2009) of NPS’s unknowability, 
based on technological innovation, and specialists in NPS pharmacology. Yet we 
argue that these solutions, were they even possible, would not solve the ‘problem’ of 
NPS, because drug treatment services do not exist only as a source of information, 
but also of particular kinds of support. As one participant noted in Glasgow,  
 
I know we’re talking about NPS particularly this morning because that’s what 
it’s about but, you know, think how we talk about dependency issues in 
general, you know, that people, it’s all come up, all the same things that 
haven’t been new, in terms of health issues, mental health issues in 
particular, access to support, to empathy, to housing, where it all comes, 
that’s the mixture of what people are looking for, not drugs-specific answers 
and we get hung up on drug-specific answers. (Glasgow Focus Group, 
emphasis added) 
 
As this frontline worker notes, it is easy to “get hung up on drug-specific answers,” 
and in that process to overlook that in terms of the social problems people present 
with (for example, physical health, mental health, housing), these are “all the same 
things that haven’t been new.” This has led some services to invest their energies in 
reinforcing existing skills:  
 
We’ve certainly had to adapt our service because of the prevalence of NPS 
and the approach we take is we’ll use Motivational Interviewing, then we’ll 
look at building a relapse prevention strategy with them, look at other 
supports you can put in place … With other drugs there is treatment 
pathways that you can go down, whereas for us, we’ve got to rely on the 
skills within the team to try and manage that and get them to take control of 
it. (Lothian Focus Group) 
 
NPS are new substances, but they do not necessarily produce new problems. As 
critical observers such as Alexandrescu (2016) and Potter and Chatwin (2018) have 
noted, the specific forms of harm may be new, but at a deeper level the ongoing 
challenges of problematic substance use and addiction relate to housing, human 
connection, physical and mental health. In a world where it simply is not possible to 
know the medium- to long-term effects of a newly emergent substance, it is possible 
to place person-centered care at the heart of drug treatment, and to work with 
clients to achieve their personal goals. Person-centered approaches that locate the 
individual as the expert on their own life and look for continuities with the harms and 
hopes of substance use and recovery rather than the new enable services to bypass 
the epistemological authority of pharmacological ways of knowing and celebrate 
their own forms of expertise for the benefit of their clients.  
 
Conclusion  
Epistemological authority lies at the heart of ‘new psychoactive substances.’ Mol 
(2002) has shown that in medicine at least, the epistemological authority of 
technologically mediated scientific ways of knowing almost always displace bodily-
mediated patient ways of knowing. She shows how atherosclerosis emerges as a 
particular sort of object through these relations, and that the ‘reality’ of 
atherosclerosis reflects the power dynamics of these relations. NPS similarly emerges 
as an object through the high value placed on scientific, and specifically 
pharmacological, ways of knowing. Attendance to these ways of knowing exposes 
these substances as new, as pharmacologically novel. Yet as this paper has sought 
to show, this is not the only way to know these substances, and attendance to the 
most marginal voices in these discussions – those of those who use them – shows 
continuity, not rupture. Listening to their stories does not construct these substances 
as new, but rather shows the ways in which the effects of these substances on 
people’s lives are not the site of dangerous, threatening unfamiliarity, but something 
that can be managed through person-centered treatment approaches.  
 
The epistemological authority of science over the subjective accounts of people who 
use drugs is not, then, merely interesting, and certainly not benign, but is itself a 
site of harm. Those possessing the authority to publish peer-reviewed, high-impact 
publications have power. Much of this work asserts a particular reality of NPS that 
bounds ‘new’ drugs from ‘old’ and prioritizes pharmacological ways of knowing over 
bodily or social ways of knowing. While those ways of knowing continue to be 
dismissed as mere “belief” and the continuities of everyday practices are devalued, 
treatment providers miss an opportunity to engage with people who use NPS in the 
terms they can engage with: meaning, values and hopes for a better future. There is 
a growing body of critical research into NPS committed to resisting the singularity of 
NPS – and through attention to the multiplicity of NPS we can begin to attend 
meaningfully to the multiplicity of people bringing them into being.  
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Table 1: Participant Demographics 
Pseudony
m 
Gende
r 
Ag
e 
At-risk 
Young 
Perso
n (YP) 
Homeles
s Person 
(HP) 
Mental 
Health 
Service 
User 
(MHSU
) 
Person 
Who 
Injects 
Drugs 
(PWID
) 
Men 
who 
have 
Sex 
with 
Men 
(MSM
) 
Alexander M 42         X 
Alistair M 28     X     
Andrea F 34     X X   
Chloe F 17 X         
Christina F 39       X   
Claire F 30   X X X   
Colin M 27     X     
Daniel M 17 X X   X   
Debbie F 22   X       
Gary M 39   X X     
Graeme M 44     X X X 
Hugh M 61       X X 
Jacob M 49     X     
James M 19 X X   X   
Jessica F 35     X X   
John M 26     X X   
Kevin M 35       X   
Kieran M 46     X     
Kimberly F 32     X X   
Luke M 20 X         
Michael M 26     X     
Michelle F 16 X         
Moira F 39       X   
Nick M 36   X       
Nicola F 32       X   
Paula F 32   X X     
Peter M 17 X X   X   
Samuel M 19 X X X     
Steven M 39   X X     
Thomas M 45       X X 
Tiffany F 28     X     
Tracey F 26     X X   
William M 55    X   X 
Total   7 10 18 16 5 
 
  
Table 2: Service type of focus group participants  
 
Service Type* N 
Drugs 20 
Young people 7 
Needle Exchange 6 
Mental Health 6 
Sexual Health 6 
Criminal Justice 6 
Housing and Homelessness 5 
Social Work 4 
* Many participants worked in services catering to more than one area. 
 
